Dongwei Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dongwei Zhu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Kanagaraj Rajalakshmi
Department of Immunology and Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Clinical Medicine & Laboratory Medicine, Jiangsu University
6 shared publications- Selvaraj Muthusamy
Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, PR China
5 shared publications Jindong Dai
Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Clinical Medicine & Laboratory Medicine, Jiangsu University
4 shared publicationsJian Shen
Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, PR China
3 shared publicationsXiaojian Liu
Department of Gynecology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, People’s Republic of China
3 shared publicationsHao Tang
Department of Clinical Laboratory, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1924756
N,S-doped carbon dots derived from tryptophan for sensitive and selective detection of meropenem in live cells, human urine, and water samples
Meropenem (MP) is an important carbapenem antibiotic used as a last-line treatment that requires precise quantification for therapeutic drug monitoring and environmental antibiotic surveillance. Herein, nitrogen, sulfur co-doped carbon dots (N,S-CDs) were derived from L-tryptophan and thiourea for MP detection. The prepared N,S-CDs were characterized by using UV–VIS, X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, high-resolution transmission electron microscopy (HR-TEM), and fluorescence spectroscopy. The interaction with MP led to systematic quenching of fluorescence (λ em = 457 nm, λ ex = 350 nm), a Stern–Volmer constant Ksv = 3.97 × 10 6 M −1 , a binding constant Ka = 9.07 × 10 6 M −1 , and a decrease in the fluorescence lifetime from 6.45 to 5.68 ns. A linear response was exhibited throughout the 0–390 nM range (R 2 = 0.990) with a limit of detection (LOD) of 6.8 nM. The sensor demonstrated high selectivity toward MP with a 1250-fold excess of coexisting inorganic ions, biomolecules, and structurally related carbapenem antibiotics. Intracellular fluorescence imaging and concentration-dependent intracellular MP detection were also demonstrated in live PC3 cells with negligible cytotoxicity (cell viability > 80% up to 10 mg/mL), indicating its potential for clinical therapeutic drug monitoring and environmental surveillance. The probe was successfully validated for the analysis of MP in pharmaceutical formulations, human serum, urine, and environmental water samples, with recoveries (%) in the range of 98%–102%. This work presents N,S-CDs as a robust, sensitive, and biocompatible analytical tool for clinical, pharmacological, and environmental MP surveillance.
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1924756
Open AccessN,S-doped carbon dots derived from tryptophan for sensitive and selective detection of meropenem in live cells, human urine, and water samples
Meropenem (MP) is an important carbapenem antibiotic used as a last-line treatment that requires precise quantification for therapeutic drug monitoring and environmental antibiotic surveillance. Herein, nitrogen, sulfur co-doped carbon dots (N,S-CDs) were derived from L-tryptophan and thiourea for MP detection. The prepared N,S-CDs were characterized by using UV–VIS, X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, high-resolution transmission electron microscopy (HR-TEM), and fluorescence spectroscopy. The interaction with MP led to systematic quenching of fluorescence (λ em = 457 nm, λ ex = 350 nm), a Stern–Volmer constant Ksv = 3.97 × 10 6 M −1 , a binding constant Ka = 9.07 × 10 6 M −1 , and a decrease in the fluorescence lifetime from 6.45 to 5.68 ns. A linear response was exhibited throughout the 0–390 nM range (R 2 = 0.990) with a limit of detection (LOD) of 6.8 nM. The sensor demonstrated high selectivity toward MP with a 1250-fold excess of coexisting inorganic ions, biomolecules, and structurally related carbapenem antibiotics. Intracellular fluorescence imaging and concentration-dependent intracellular MP detection were also demonstrated in live PC3 cells with negligible cytotoxicity (cell viability > 80% up to 10 mg/mL), indicating its potential for clinical therapeutic drug monitoring and environmental surveillance. The probe was successfully validated for the analysis of MP in pharmaceutical formulations, human serum, urine, and environmental water samples, with recoveries (%) in the range of 98%–102%. This work presents N,S-CDs as a robust, sensitive, and biocompatible analytical tool for clinical, pharmacological, and environmental MP surveillance.
- Open Access
- 24 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (11) , 1552
When VacA Meets Immune Cells: Beyond Vacuolation
Vacuolating cytotoxin A (VacA) is a critical virulence factor of Helicobacter pylori and is closely associated with chronic gastric diseases and gastric cancer. This review systematically summarizes the gene polymorphism, protein structure, functional characteristics, cellular receptors, and vacuolation mechanism of VacA. VacA interacts with diverse immune cells including T cells, B cells, macrophages, dendritic cells and neutrophils, reshaping the immune microenvironment to facilitate the immune evasion and persistent colonization of H. pylori. The genotypic polymorphisms of VacA correlate with the severity of gastric lesions and gastric cancer risk. At present, VacA can be applied in the auxiliary risk stratification of gastric cancer and rapid virulence genotyping. Nevertheless, specific inhibitors and vaccines targeting VacA remain in pre-clinical exploration and are not routinely used in clinical practice. Further investigation into its immunomodulatory molecular mechanisms will provide novel insights for the prevention and treatment of H. pylori-associated diseases.
- 24 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (11) , 1552
Open AccessWhen VacA Meets Immune Cells: Beyond Vacuolation
Vacuolating cytotoxin A (VacA) is a critical virulence factor of Helicobacter pylori and is closely associated with chronic gastric diseases and gastric cancer. This review systematically summarizes the gene polymorphism, protein structure, functional characteristics, cellular receptors, and vacuolation mechanism of VacA. VacA interacts with diverse immune cells including T cells, B cells, macrophages, dendritic cells and neutrophils, reshaping the immune microenvironment to facilitate the immune evasion and persistent colonization of H. pylori. The genotypic polymorphisms of VacA correlate with the severity of gastric lesions and gastric cancer risk. At present, VacA can be applied in the auxiliary risk stratification of gastric cancer and rapid virulence genotyping. Nevertheless, specific inhibitors and vaccines targeting VacA remain in pre-clinical exploration and are not routinely used in clinical practice. Further investigation into its immunomodulatory molecular mechanisms will provide novel insights for the prevention and treatment of H. pylori-associated diseases.
- Open Access
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1895048
Targeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers
Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints resulting in inflammation, pain and progressive disability. Immunological imbalance, especially the stimulation of pathogenic immune cells, including T and B cells, macrophages, amongst others, is the cause of the disease, as it is critical to the development of the disease. The limitation of traditional anti-RA medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), in the treatment of the disease led to the development of more specific medicines. One of the most promising biologic agents, including monoclonal antibodies, cytokine inhibitors and cell-based therapies, are specifically targeting immune cells and inflammatory pathways in RA. This review examines these new immunotherapies, their mechanisms of action, clinical efficacy, and challenges associated with them, including resistance to treatment, safety issues, and the necessity to use personalised therapy. Also, the new immunotherapeutic approaches, which include targeting autoantibodies, gene therapy, and precision medicine, are promising new approaches that could result in more effective and personalised treatments. Finally, the review concludes with a discussion of future directions, where in combination therapies, next-generation biologics, and personalised treatment regimens are also possible and can change the way RA can be managed in the future. To preserve analytical depth, this review explicitly distinguishes established (regulatory-approved) therapies from investigational and experimental approaches and indicates the level of clinical evidence for each.
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1895048
Open AccessTargeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers
Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints resulting in inflammation, pain and progressive disability. Immunological imbalance, especially the stimulation of pathogenic immune cells, including T and B cells, macrophages, amongst others, is the cause of the disease, as it is critical to the development of the disease. The limitation of traditional anti-RA medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), in the treatment of the disease led to the development of more specific medicines. One of the most promising biologic agents, including monoclonal antibodies, cytokine inhibitors and cell-based therapies, are specifically targeting immune cells and inflammatory pathways in RA. This review examines these new immunotherapies, their mechanisms of action, clinical efficacy, and challenges associated with them, including resistance to treatment, safety issues, and the necessity to use personalised therapy. Also, the new immunotherapeutic approaches, which include targeting autoantibodies, gene therapy, and precision medicine, are promising new approaches that could result in more effective and personalised treatments. Finally, the review concludes with a discussion of future directions, where in combination therapies, next-generation biologics, and personalised treatment regimens are also possible and can change the way RA can be managed in the future. To preserve analytical depth, this review explicitly distinguishes established (regulatory-approved) therapies from investigational and experimental approaches and indicates the level of clinical evidence for each.
- Open Access
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1780357
Strategic applications of heterocyclic compounds in pharmaceutical innovation: a business perspective
The heterocyclic compound is one of the finest spanned backbones for developing most innovative agents in the pharmaceutical industry. These adaptable molecules have played an important role in the discovery of therapeutic agents of a wide range, including antibiotics, anticancer drugs and antivirals. The role of heterocyclic chemistry in pharmaceutical innovation is thus one that extends beyond mere structural complexity but contributes significantly to improved therapeutic index, and in doing so stimulates economic activity in the field. The medicinal significance of heterocycles, their role in drug discovery, and their commercial prospects are discussed in the Research article. It explores types of heterocyclic compounds, its historical importance, influence on the world health and market trends delivering its industrial usage. Synthetic challenges, regulatory hurdles, and sustainability concerns are discussed in tandem with future opportunities that may arise from advancements in green synthesis and artificial intelligence (AI)-driven drug discovery. This study emphasizes the transformative potential of heterocyclic compounds in modern medicine by connecting their scientific advancements to business strategies.
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1780357
Open AccessStrategic applications of heterocyclic compounds in pharmaceutical innovation: a business perspective
The heterocyclic compound is one of the finest spanned backbones for developing most innovative agents in the pharmaceutical industry. These adaptable molecules have played an important role in the discovery of therapeutic agents of a wide range, including antibiotics, anticancer drugs and antivirals. The role of heterocyclic chemistry in pharmaceutical innovation is thus one that extends beyond mere structural complexity but contributes significantly to improved therapeutic index, and in doing so stimulates economic activity in the field. The medicinal significance of heterocycles, their role in drug discovery, and their commercial prospects are discussed in the Research article. It explores types of heterocyclic compounds, its historical importance, influence on the world health and market trends delivering its industrial usage. Synthetic challenges, regulatory hurdles, and sustainability concerns are discussed in tandem with future opportunities that may arise from advancements in green synthesis and artificial intelligence (AI)-driven drug discovery. This study emphasizes the transformative potential of heterocyclic compounds in modern medicine by connecting their scientific advancements to business strategies.
- 9 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 353, 151275
1,3,5-Triazine functionalized chitosan encapsulated nanocomposite for electrochemical dual detection of glucose and H2O2
- 9 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 353, 151275
1,3,5-Triazine functionalized chitosan encapsulated nanocomposite for electrochemical dual detection of glucose and H2O2
- 30 October 2025
- Published by Springer Nature in Silicon
- Vol. 17 (17) , 4059-4070
Functionalization of Halo-Hydroxy Benzimidazole onto SiO2 Nanoparticles: Catalytic, Photophysical, and Biological Investigations for Sustainable Applications
- 30 October 2025
- Published by Springer Nature in Silicon
- Vol. 17 (17) , 4059-4070
Functionalization of Halo-Hydroxy Benzimidazole onto SiO2 Nanoparticles: Catalytic, Photophysical, and Biological Investigations for Sustainable Applications
- 29 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109167
Design, synthesis, bioactivity evaluation, and molecular modeling of pyridin-2-yl-pyrimidine: Potential Antimicrobial and anti-tuberculosis agents
- 29 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109167
Design, synthesis, bioactivity evaluation, and molecular modeling of pyridin-2-yl-pyrimidine: Potential Antimicrobial and anti-tuberculosis agents
- 1 August 2025
- Published by Springer Nature in Silicon
- Vol. 17 (14) , 3309-3316
Silicon Dioxide Functionalized with Benzimidazole: A Versatile Dual-Function Sensor and Enhanced Antimicrobial Agent
- 1 August 2025
- Published by Springer Nature in Silicon
- Vol. 17 (14) , 3309-3316
Silicon Dioxide Functionalized with Benzimidazole: A Versatile Dual-Function Sensor and Enhanced Antimicrobial Agent
- 25 June 2025
- Published by Elsevier in Food Chemistry
- Vol. 492 (Pt 1) , 145337
Sensitive determination of caffeoylquinic acid in food and blood samples using nanostructured conducting polymer composite modified electrode
- 25 June 2025
- Published by Elsevier in Food Chemistry
- Vol. 492 (Pt 1) , 145337
Sensitive determination of caffeoylquinic acid in food and blood samples using nanostructured conducting polymer composite modified electrode